請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36585完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 曾麗慧 | |
| dc.contributor.author | Ching-Yi Lin | en |
| dc.contributor.author | 林靜儀 | zh_TW |
| dc.date.accessioned | 2021-06-13T08:06:39Z | - |
| dc.date.available | 2005-08-02 | |
| dc.date.copyright | 2005-08-02 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-21 | |
| dc.identifier.citation | Abushoufa RA, Talbot JA, Brownbill K, et al. The development of a sialic acid specific lectin-immunoassay for the measurement of human chorionic gonadotropin gylcofroms in serum and its application in normal and Down’s syndrome pregnancies. Clin Endocrinol 2000;52:499.
ACOG Practice Bulletin: Prenatal diagnosis of fetal chromosomal abnormalities. Clinical management for Obstetricians-Gynecologists Obstetrics and Gynecology Number 27. Obstet Gynecol 2001;97:1 Bartha JL, Omar KM, Soothill PW. The relationship between maternal serum alpha-fetoprotein and maternal haemoglobin. Prenat Diagn 2004;24:609. Beekhuis J, Van Lith J, De Wolf B, Mantingh A. Increased maternal serum alpha-fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects of Down syndrome. Prenat Diagn 1992;12:643. Beischer NA, Sivasamboo R, Vohra S, Silpisornkosal S, Reid S. Placental hypertrophy in severe pregnancy anaemia. J Obstet Gynecol Br Commw 1970;77:398. Benn PA, Gainey A, Ingardia CJ, Rodis JF, Egan JF. Second trimester maternal serum analyted in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn 2001;21(8):680. Benn PA, Leo MV, Rodis JF, et al. maternal serum screening for fetal trisomy 18. A comparison of fixed cutoff and patient specific risk protocols. Obstet Gynecol 1999;93(5):707. Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7:623. Burton GJ, Reshetnikova OS, Milovano AP, Teleshova OV. Stereological evaluation of vascular adaptations in human placental villi to differing forms of hypoxic stress. Placenta 1996;17(1);49. Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimeste maternal serum unconjugated oestriol in pregnancies with Down syndrome. Br J Obstet Gynecol 1988;95:300. Centers for Disease Control: CDC criteria for anemia in children and childbearing-aged women. MMWR 1989;38:400. Chao AS, Chung CL, Wu CD, et al. Second trimester maternal serum screening using alpha fetoprotein, free beta human chorionic gonadotropin and maternal age specific risk: result of chromosomal abnormalities detected in screen positive for Down syndrome in an Asian population. Acta Obstet Gynecol Scand 1999;78:393. Chen CP, Lin CJ, Wang W. Impact of second-trimester maternal serum screening on prenatal diagnosis of Down syndrome and the use of amniocentesis in the Taiwanese population. Taiwanese J Obstet Gynecol 2005;44(1):31 Chen CP, Shih JC, Chern SR, Lee CC, Wang W. Prenatal diagnosis of mosaic trisomy 16 associated with congenital diaphragmatic hernia and elevated maternal serum alpha-fetoprotein and human chorionic gonadotrophin. Prenat Diagn 2004;24:63. Cheng EY, Luthy DA, Zebelman AM, Williams MA, Luppman RE, Hickok ED. A prospective evaluation of a second trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol 1993;81:72. Cheng PJ, Liu CM, Chang SD, Lin YT, Soong YK. Elevated second-trimester maternal serum hCG in patients undergoing haemodialysis. Prenat Diagn 1999;19:955. Cheng PJ, Chu DC, Chueh HY, See LC, Chang HC, Weng DR. Elevated maternal midtrimester serum free β-human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results. Am J Obstet Gynecol 2004;190(2);442 Chu DC, Hsu C, Wenstrom KD, Boots LR. Insulin-like growth factor binding protein-3 in the detection of fetal Down syndrome pregnancies. Obstet Gynecol 1998;91(2):192. Cuckle HS. Improved parameters for the risk estimation in Down’s syndrome screening. Prenat Diagn 1995;15:1057. Cuckle HS, Iles RK, Sehmi IK et al. Urinary multiple marker screening for Down’s syndrome. Prenat Diagn 1995;15:745. Cuckle HS, Schmi I, Jones R, et al. Maternal serum activin A and follistatin levels in pregnancies with Down syndrome. Prenat Diagn 1999;19:513. Ferguson-Smith MA, Yates JR. Maternal age specific rates for chromosome aberrations and factors influencing them: Report of a collaborative European study in 52,965 amniocentesis. Prenat Diagn 1984;4:44. Godfrey KM, Redman CWG, Osmond C. The effect of maternal anaemia and iron deficiency on the ratio of feta weight to placental weight. Br J Obstet Gynaecol 1991;98:886. Haddow JE, Palomaki GE, Knight GJ, Canick JA. Maternal serum unconjugated estriol levels are lower in the presence of fetal Down syndrome. Am J Obstet Gynecol 1990;163:1372. Haddow JE, Palmaki BS, Knight GJ, et al. Prenatal screening for Down’s syndrome with use of maternal serum markers. N Eng J Med 1992;327:588. Howe DT, Wheeler T, Osmond C. The influence of maternal haemoglobin and ferritin on mid-pregnancy placental volume. Br J Obstet Gynecol 1995;102:213. Huang A, Zhang R, Yang Z. Quantitative (stereological) study of placenta structures in women with pregnancy iron-deficiency anemia. Eur J Obstet Gynecol Reprod Biol 2001;97:59. Jou HJ, Shyu MK, Chen SM, Shih JC, Hsu JJ, Hsieh FJ. Maternal serum screening for Down syndrome by using alpha-fetoprotein and human chorionic gonadotropin in an Asian population. Fetal Diagn Ther 2000;15:108. Katz VL, Ghescheir NC, Cefalo RC. Unexplained elevations of maternal serum alpha-fetoprotein. Obstet Gynecol Surv 1990;45:719. Kadyrov M, Kosanke G, Kingdom J, Kaufmann P. Increased fetoplacenta angiogenesis during first trimester in anaemic women. Lancet 1998;352:1747. Kingdom JCP, Kaufmann P. Oxygen and placental villous development: origins of fetal hypoxia. Placenta 1997; 18:613. Kishida T, Hoshi N, Hattori R, et al. Efficacy of maternal serum screening in the prenatal detection of fetal chromosome abnormalities in Japanese women. Fetal Diagn Ther 2000;15:112. Klebanoff MA, Shiono PH, Selby JV, Trachtenberg AI, Graubard BI. Anemia and spontaneous preterm birth. Am J Obstet Gynecol 1991;164:59. Kramer RL, Yaron Y, O’Brien JE et al. Effect of adjustment of maternal serum alpha-retoprotein levels in insulin-dependent diabetes mellitus. Am J Med Genet 1998;75:176. Krause T, Christens P, Wohfgahrt J et al. Second-trimester maternal serum alpha-fetoprotein and risk of adverse pregnancy. Obstet Gynecol 2001;97:277. Leke L, Kremp D. Impact of nutritional deficiencies on anemia in pregnant women. Dev Sante 1989;84:4. Lieberman E, Ryan KJ, Monson RR, Schoenbaum SC. Risk factors accounting for racial differences in the rate of premature birth. N Eng J Med 1987;317:743. Laundon CH, Spencer K, Macri JN, Anderson RW, Buchanan PD. Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies. Prenat Diagn1996;16(9):853. Mayhew TM. Patterns of villous and intervillous space growth in human placentas from normal and abnormal pregnancies. Eur J Obstet Gynecol Reprod Biol 1996;68:75. Mayhew TM. Changes in fetal capillaries during preplacental hypoxia: growth, shape remodeling and villous capillarization in placentae from high-altitude pregnancies. Placenta 2003;24:191. Maymon R, Cuckle H, Sehmi IK, Herman A, Sherman D: Maternal serum human chorionic gonadotropin levels in systemic lupus erythematosus and antiphospholipid syndrome. Prenat Diagn 2001;21:143. Maymon R, Shulman A. Serial first- and second-trimester Down’s syndrome screening tests among IVF-versus naturally conceived singletons. Hum Reprod 2002;17:1081. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 1984;148:886. Meyers C, Adam R, Dungan J, Prenger V. Aneuploidy in twin gestations: when is maternal age advanced? Obstet Gynaecol 1997;89:248. Michailidis GD, Morris RW, Mamopoulos A, Papageorgiou P, Economides DL. The influence of maternal hematocrit on placental development from the first to the second trimesters of pregnancy. Ultrasound Obstet Gynecol 2002;20:351. Moroz C, Maymon R, Jauniaux E, Traub L, Cuckle H. Screening for trisomies 21 and 18 with maternal serum placental isoferritin p43 component. Prenat Diagn 2000;20:395. Muller F, Dreux S, Dupoizat H, et al. Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity. Prenat Diagn 2003;23:331. Muller F, Dreux S, Lemeur A, et al. Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome. Prenat Diagn 2003;23:1073. Nicolini U, Hubinont C, Santoyala J, Fisk NM, Rodeck CH, Johnson RD. Fetal serum alpha-fetoprotein in fetuses with chromosomal abnormalities. Lancet 1988;ii:1316. O’Brien JE, Dvorin E, Drugan A, et al. Race-ethnicity specific variation in multiple-marker biochemical screening: alpha-fetoprotein, hCG, and estriol. Obstet Gynecol 1997;89:355. Ochshorn Y, Kupferminc MJ, Eldor A, et al. Second-trimester maternal serum alpha-fetoprotein (MSAFP) is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias. Prenat Diagn 2001;21;658. Palomaki GE, Neveux LE, Knight GJ, Haddow JE. Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers. Prenat Diagn 2003;23:243. Perelman N, Selvaral SK, Batra S, et al. Placenta growth factor activates monocytes and correlated with sickle cell disease severity. Blood 2003;102(4):1506. Perona M, Mancini G, Dall’Amico D, et al. Influence of smoking habits on Down’s syndrome risk evaluation at mid-trimester through biochemical screening. Int J Clin Lab Res 1998;28:179. Petrocik E, Wassman ER, Kelly JC. Prenatal screening for Down syndrome with maternal serum human chorionic gonadotropin levels. Am J Obstet Gynecol 1989;161:1168 Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol 1992;80:353. Puolakka J, Janne O, Pakariene A, et al. Serum ferritin in the diagnosis of anemia during pregnancy. Acta Obstet Gynecol Scand 1980;95(suppl):57. Räty R, Koshinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U. Prediction of preeclampsia with maternal mid-trimester total rennin, inhibin A, AFP and free β-hCG levels. Prenat Diagn 1999;19:122. Räty R, Virtanen A, Koskinen P, et al. Serum free β-hCG and alpha-fetoprotein levels in IVF, ICSI and frozen embryo transfer pregnancies in maternal mid-trimester serum screening for Down’s syndrome. Hum Reprod 2002;17:481. Reshetnikova OS, Burton GJ, Teleshova OV. Placenta histomorphometry and morphometric diffusion capacity of the villous membrane in pregnancies complicated by maternal iron-deficiency anemia. Am J Obstet Gynecol 1995;173:724. Sanders RC. Structural fetal abnormalities, 2nd ed. Missouri, Modby.2002:p11. Scholl TO. High third-trimester ferritin concentration: associations with very preterm delivery, infection, and maternal nutritioal status. Obstet Gynecol 1998;92:161 Spencer K. Second trimester prenatal screening for Down syndrome using alpha-fetoprotein and free beta hCG: a seven year review. BJOG 1999;106:1287. Spencer K. Second trimester prenatal screening for Down syndrome and the relationship of maternal serum biochemical markers to pregnancy complications with adverse outcome. Prenat Diagn 2000;20:652. Su YN, Hsu JJ, Lee CN, Cheng WF, Kung CC, Hsieh FJ. Raised maternal serum placenta growth factor concentration during he second trimester is associated with Down syndrome. Prenat Diagn 2002;22:8. Sutton JM, Cole LA. Sialic acid-deficient invasive trophoblast antigen (sd-ITA): a new urinary variant for gestational Down syndrome screening. Prenat Diagn 2004;24:194. Swain S, Singh S, Bhatia BD, Pandey S, Krishna M. Maternal hemoglobin and serum albumin and fetal growth. Indian Pediatr 1994;31(7):777. Tsu TY, Ou CY, Hsu JJ, et al. Maternal serum screening for Down syndrome in pregnancies conceived by intra-uterine insemination. Prenat Diagn. 1999 Nov;19(11):1012 Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ. Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol 1998;179:1539. Vintzileos AM, Ananth CV, Smulian JC, et al. Cost-benefit analysis of prenatal diagnosis for Down syndrome using the British or American approach. Obstet Gynecol 2000;95:577-83. Viteri FE. The consequences of iron deficiency and anemia in pregnancy. Adv Exp Med Biol 1994;352:127. Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum screening for Down’s syndrome in early pregnancy. Br Med J 1988;297:883. Wald NJ, Densem JM, George L, Muttukrishna S, Knight PG. Prenatal screening for Down’s syndrome using inhibin-A as a serum marker. Prenat Diagn 1996;16:143 Wald NJ, Kennard A, Hackshaw S, et al. Antenatal screening for Down’s syndrome. J Med Screen 1997;4:181. Wald NJ, Hackshaw AK, Diamandis EP, et al. Maternal serum prostate-specific antigen and Down syndrome in the first and second trimesters of pregnancy. International Prenatal Screening Research Group. Prenat Diagn 1999;19:674. Wald NJ, Huttly WJ, Rudnicka AR. Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenat Diagn 2004;24:389 .Wald NJ, White N, Morris JK, Huttly WJ, Canick JA. Serum markers for Down’s syndrome in women who have had in vitro fertilization: implications for antenatal screening. BJOG 1999;106:1304. Wen CP, Cheng TY, Lin CL, et al. The health benefits of smoking cessation for adult smokers and for pregnant women in Taiwan. Tob Control. 2005 Jun;14 Suppl 1:i56. Wenstrom KD, Williamson RA, Grant SS, Hudson JD, Getchell JP. Evaluation of multiple-marker screening for Down syndrome in a statewide population. Am J Obstet Gynecol 1993;169:793. Wenstrom KD, Williamson RA, Grant SS. Detection of fetal Tuner syndrome with multiple-marker screening. Am J Obstet Gynecol 1994;170(2):570. Wenstrom KD, Owen J, Chu V, Boots L. Alpha Fetoprotein, free β-human chorionic gonadotropin, and dimeric inhibin A produce the best results in a three-analyte, multiple-marker screening test for fetal Down syndrome. Am J Obstet Gynecol 1997;177:987. Wheeler T, Sollero C, Alderman S, Landen J, Anthony F, Osmond C. Relation between maternal haemoglobin and placental hormone concentration in early pregnancy. Lancet 1994. Williams LA, Evans SF, Newnham JP. Prospective cohort study of factors influencing the relative weights of the placenta and the newnorn infant. BMJ 1997;314:1864. Yaron Y, Kramer R, O’Brien J, Hallak M, Johncon M, Evans M. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations a predictors of pregnancy outcome. Am J Obstet Gymecol 1999;181:968. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36585 | - |
| dc.description.abstract | 研究目的: 討論懷孕婦女貧血是否影響妊娠中期母血唐氏症篩檢結果。
研究對象及方法:以中山醫學大學附設醫院產前門診作描述型研究，收集自2001年9月至2004年12月完整產前檢查及母血唐氏症篩檢結果之單胞懷孕婦女。以妊娠初期產前檢查結果區分成貧血及未貧血婦女，比較組間妊娠中期母血唐氏症篩檢之血清中free β-hCG及α-fetoprotein之 multiples of the median values (MoM值)。同時比較組間母血唐氏症篩檢偽陽性率之差別。 研究結果: 研究納入948名含有完整檢查及分娩紀錄之單胞懷孕婦女。有107名為貧血, 平均hemoglobin為10.26±0.66 g/dL, 841名非貧血婦女則平均hemoglobin為12.38±0.76 g/dL. 有43名婦女的唐氏症篩檢結果陽性(懷唐氏症胎兒機率大於1/270)，胎兒染色體經分析均為正常；母血唐氏症篩檢偽陽性率為4.54%。貧血婦女的母血篩檢偽陽性率為5.61%而非貧血婦女的母血篩檢偽陽性率為4.40%，Odds ratio 1.26 (95%CI 0.53 to 3.13, p>0.05)，二組間沒有顯著差異。 結論: 此研究顯示母血唐氏症篩檢在貧血婦女相較於未貧血者並未發現顯著差異的偽陽性率。貧血並不影響妊娠中期母血唐症篩檢。 | zh_TW |
| dc.description.abstract | Objectives: The aim of this study is to examine the relation between maternal anemia and the results of second trimester maternal serum screening for Down syndrome.
Subjects and Methods: This descriptive study included singleton pregnant women’s prenatal examination data in Chung-Shan Medical University Hospital Prenatal Care Clinic from September 2001 to December 2004. The second trimester maternal serum free β-human chorionic gonadotropin (hCG) levels and α-fetoprotein levels (MSAFP) multiples of the median (MoM) values in anemia pregnancies group were compared with non-anemia pregnancies group. At the same time, we compared the false-positive rate of maternal serum screening for Down syndrome in anemia pregnancies with non-anemia pregnancies. Results: Nine hundreds and forty eight of first trimester maternal hemoglobin (Hb) data and second trimester maternal serum screening results were collected from singleton pregnant women. There were 107 of anemia women with the mean hemoglobin concentration 10.26±0.66 g/dL, 841 of non-anemia women with the mean hemoglobin concentration 12.38±0.76 g/dL. There were 43 women with “positive results” (the risk > 1/270) of maternal serum screening for Down syndrome and carried normal karyotypes of the fetus. The false positive rate of maternal serum screening was 4.54% in study subject. The false positive rates were 5.61% and 4.40% in anemia women and non-anemia women, the Odds ratio 1.26 (95%CI 0.53 to 3.13, p>0.05). There was not significant difference between anemia and false positive result of maternal serum screening for Down syndrome. Conclusion: This present study did not revealed significant elevated false positive rate of second trimester maternal serum screening for Down syndrome in anemia pregnancy detected during first trimester. Anemia does not interfere second trimester maternal serum screening result for Down syndrome. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T08:06:39Z (GMT). No. of bitstreams: 1 ntu-94-P92448002-1.pdf: 391106 bytes, checksum: 3f846215bcb6778a45608489cfdb68ba (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 口試委員、指導教授及所長簽名表
國家圖書館碩博士論文授權書 Acknowledgment --------------------------------------------------------------------------- 2 English Abstract ---------------------------------------------------------------------------- 4 Chinese Abstract --------------------------------------------------------------------------- 5 Introduction --------------------------------------------------------------------------------- 6 Study problems Background/Literature Review Subjects and Methods ------------------------------------------------------------------- 12 Statistical Consideration Ethical Consideration Results ------------------------------------------------------------------------------------- 14 Discussion --------------------------------------------------------------------------------- 16 Reference ---------------------------------------------------------------------------------- 22 Table 1 and Figure 1-1, 1-2, 1-3, 1-4. Mean maternal age, Hb concentrations and MCV levels, and number of positive and normal results of second trimester maternal screening for Down syndrome. ------------------------ 29 Table 2 and Figure 2-1, 2-2. Demographics and results in anemia and non-anemia pregnancies in 948 subjects. -------------------------------------------------- 33 Table 3 and Figure 3-1, 3-2, 3-3, 3-4. Demographics and results of MSAFP and maternal serum free b-hCG in anemia and non-anemia pregnancies. --- 36 Table 4 and Figure 4-1, 4-2, 4-3, 4-4. Demographics and results of MSAFP and free b-hCG in pregnancies with false positive results and normal results of maternal serum screening for Down syndrome. ------------------------ 41 Table 5 and Figure 5-1, 5-2. Demographics and results of MSAFP and maternal serum free b-hCG in different Hb levels pregnancies. -------------------- 46 | |
| dc.language.iso | en | |
| dc.title | 早期妊娠貧血與母血唐氏症篩檢偽陽性率之關聯 | zh_TW |
| dc.title | Maternal anemia and the false positive rate of maternal serum screening for Down syndrome | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 林隆堯,陳持平,徐振傑 | |
| dc.subject.keyword | 貧血,唐氏症,染色體異常,產前篩檢,甲型胎兒蛋白,人類絨毛膜激素, | zh_TW |
| dc.subject.keyword | anemia,Down syndrome,trisomy 21,prenatal screen,AFP,hCG, | en |
| dc.relation.page | 48 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-07-21 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 分子醫學研究所 | zh_TW |
| 顯示於系所單位： | 分子醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-94-1.pdf 目前未授權公開取用 | 381.94 kB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。